Commonly mutated gene could be a therapeutic target in sarcoma
Researchers at The University of Texas MD Anderson Cancer Center have discovered that sarcomas lacking the ATRX gene tend to be more aggressive and may be particularly vulnerable to a class of targeted therapies known as TEAD inhibitors. The findings identify ATRX loss as both a marker of poor prognosis and a potential therapeutic target.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.